Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A promising "one-and-done" CAR T-cell therapy is turning heads in AL amyloidosis treatment. Interim data from the NEXICART-2 trial show NXC-201 achieved an 89% complete response rate in relapsed/refractory AL amyloidosis patients — with the potential to climb to 98%. No relapses have been observed among responders, and the therapy showed a favorable safety profile with no neurotoxicity reported.
A BCMA-directed CAR T-cell therapy could be a game-changer for patients with relapsed/refractory AL amyloidosis — a rare and serious condition where abnormal proteins damage vital organs. Interim data from the phase 1b/2 NEXICART-2 trial show that NXC-201 achieved an 89% complete response (CR) rate across 45 evaluable patients, with no relapses observed among those who responded. Notably, all patients who previously achieved MRD (minimal residual disease) negativity went on to reach a full CR within one year.
The therapy's safety profile also stood out: no neurotoxicity or enterocolitis was reported — a meaningful distinction in the CAR T-cell space. Immix Biopharma plans to submit a Biologics License Application (BLA) to the FDA following final data readout expected in 2027. NXC-201 already holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Orphan Drug designations from the FDA.
By the Numbers:
Why it matters: AL amyloidosis currently requires years of continuous treatment with no curative options for most patients. NXC-201's near-complete response rates and durable remissions could represent a true one-time treatment solution for a disease with very limited alternatives.
